- Home
- / Neoleukin Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Neoleukin Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.5
2023-12-19
Market Capitalization
$8.2 M
2023-12-19
Revenue
$925 K
FY, 2024
CreditSafe Score
?
Score changed on Jun 14, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.0M | 925.0K | ||||||||||
| General and administrative expense | 4.3M | 5.5M | 9.3M | 14.9M | 15.8M | 18.8M | 17.2M | 21.5M | 18.0M | 11.2M | 22.6M | 28.3M |
| Operating expense total | 22.4M | 21.3M | 37.6M | 51.1M | 57.6M | 18.8M | 41.6M | 59.1M | 83.5M | 103.3M | ||
| EBIT | (32.6M) | (71.0M) | (59.1M) | (55.6M) | (82.6M) | (103.3M) | ||||||
| EBIT margin, % | -130.5% | -8930.3% | ||||||||||
| Interest income | 3.0M | 8.5M | 11.5M | |||||||||
| Interest expense | 1.6M | 12.0K | 12.0K | 5.0K | ||||||||
| Pre tax profit | (24.0M) | (21.9M) | (37.0M) | (50.2M) | (31.6M) | (69.4M) | (33.3M) | (60.7M) | (57.6M) | (36.3M) | (75.1M) | (90.4M) |
| Income tax expense | (222.0) | |||||||||||
| Net Income | (24.0M) | (21.9M) | (37.0M) | (50.2M) | (31.6M) | (69.4M) | (33.3M) | (60.7M) | (57.6M) | (36.3M) | (75.1M) | (90.4M) |
| EPS | (1.0) | (4.3) | (4.2) |